Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

Post by: Geert in Immunic Press Release
Immunic, Inc. Reports that IMU-838,…
read more
22 Apr 2020
0

iTeos Therapeutics Closes $125 Million Series B2 Financing

Post by: Geert in iTeos Press Release
iTeos Therapeutics Closes $125 Million…
read more
03 Apr 2020
0

eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

Post by: Geert in eTheRNA Press Release
eTheRNA launches an international consortium…
read more
24 Mar 2020
0

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies

Post by: Geert in Horama Press Release
HORAMA Signs Exclusive License Agreement…
read more
19 Mar 2020
0

Job opening at Fund+ / Internship

Post by: Geert in Fund+ Jobs
Job opening Internship Fund+ is…
read more
13 Mar 2020
0

Job opening at Fund+ / Senior Associate

Post by: Geert in Fund+ Jobs
Job opening Senior Associate Fund+…
read more
13 Mar 2020
0

HORAMA strengthens its management team with the appointment of Rodolphe Clerval as Chief Business Officer (CBO)

Post by: Geert in Horama Press Release
HORAMA strengthens its management team…
read more
13 Mar 2020
0

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

Post by: Geert in iTeos Press Release
iTeos Therapeutics Initiates Phase 1/2 Study…
read more
28 Feb 2020
0

Minoryx Therapeutics in the news

Post by: Geert in Minoryx News article
Minoryx Therapeutics in the news
read more
18 Feb 2020
0

La Wallonie octroie 15 millions à iTeos

Post by: Geert in iTeos News article
La Wallonie octroie 15 millions…
read more
31 Jan 2020
0